206 related articles for article (PubMed ID: 34924303)
1. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
Søgaard M; Nielsen PB; Skjøth F; Larsen TB; Eldrup N
Eur J Vasc Endovasc Surg; 2022 Feb; 63(2):285-294. PubMed ID: 34924303
[TBL] [Abstract][Full Text] [Related]
2. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
[TBL] [Abstract][Full Text] [Related]
4. Editor's Choice - Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD.
Aboyans V; Morboeuf O; Grenier B; Jolivel R; Bura-Riviere A
Eur J Vasc Endovasc Surg; 2024 Jun; 67(6):969-978. PubMed ID: 38316351
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Krantz MJ; Debus SE; Hsia J; Patel MR; Anand SS; Nehler MR; Hess CN; Capell WH; Bracken T; Szarek M; Mátyás L; Krievins DK; Nault P; Stefanov S; Haskell LP; Berkowitz SD; Muehlhofer E; Hiatt WR; Bauersachs RM; Bonaca MP
Eur Heart J; 2021 Oct; 42(39):4040-4048. PubMed ID: 34430972
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
[TBL] [Abstract][Full Text] [Related]
9. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
Bauersachs RM; Szarek M; Brodmann M; Gudz I; Debus ES; Nehler MR; Anand SS; Patel MR; Hess CN; Capell WH; Rogers K; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP;
J Am Coll Cardiol; 2021 Jul; 78(4):317-326. PubMed ID: 34010631
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Govsyeyev N; Nehler M; Conte MS; Debus S; Chung J; Dorigo W; Gudz I; Krievins D; Mills J; Moll F; Norgren L; Piffaretti G; Powell R; Szalay D; Sillesen H; Wohlauer M; Szarek M; Bauersachs RM; Anand SS; Patel MR; Capell WH; Jaeger N; Hess CN; Muehlhofer E; Haskell LP; Berkowitz SD; Bonaca MP
J Vasc Surg; 2023 Apr; 77(4):1107-1118.e2. PubMed ID: 36470531
[TBL] [Abstract][Full Text] [Related]
13. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
[TBL] [Abstract][Full Text] [Related]
14. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Yuan Z; Levitan B; Deng H; Szarek M; Bauersachs RM; Berkowitz SD; Haskell L; Barnathan ES; Bonaca MP
J Am Heart Assoc; 2024 Apr; 13(8):e032782. PubMed ID: 38563380
[TBL] [Abstract][Full Text] [Related]
16. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Darmon A; Bhatt DL; Elbez Y; Aboyans V; Anand S; Bosch J; Branch KR; Connolly SJ; Dyal L; Eikelboom JW; Fox KAA; Keltai K; Probstfield J; Yusuf S; Abtan J; Sorbets E; Eagle KA; Ducrocq G; Steg PG
Eur Heart J; 2018 Mar; 39(9):750-757a. PubMed ID: 29186454
[TBL] [Abstract][Full Text] [Related]
17. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Bonaca MP; Szarek M; Debus ES; Nehler MR; Patel MR; Anand SS; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM
Clin Cardiol; 2022 Dec; 45(12):1143-1146. PubMed ID: 36251249
[TBL] [Abstract][Full Text] [Related]
19. VOYAGER PAD contributes to medical therapy for peripheral artery disease.
Farber A
J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822
[No Abstract] [Full Text] [Related]
20. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
